We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-7.68%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$904M
AUM Growth
-$241M
Cap. Flow
-$51.9M
Cap. Flow %
-5.75%
Top 10 Hldgs %
69.85%
Holding
45
New
4
Increased
7
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$16.9M
2
PACB icon
Pacific Biosciences
PACB
+$11.8M
3
RLAY icon
Relay Therapeutics
RLAY
+$9.95M
4
VERV
Verve Therapeutics
VERV
+$9.57M
5
GPCR icon
Structure Therapeutics
GPCR
+$8.42M

Top Sells

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$31.2M
2
ILMN icon
Illumina
ILMN
+$22M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$15.3M
4
BPMC
Blueprint Medicines
BPMC
+$13.3M
5
MXCT icon
MaxCyte
MXCT
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
1
Sarepta Therapeutics
SRPT
$1.63B
$122M 13.55%
1,010,330
-4,670
-0.5% -$528K
BLFS icon
2
BioLife Solutions
BLFS
$1.56B
$107M 11.89%
7,780,000
+58,465
+0.8% +$921K
EQRX
3
DELISTED
EQRx, Inc. Common Stock
EQRX
$87.8M 9.71%
39,527,669
– –
GPCR icon
4
Structure Therapeutics
GPCR
$3.39B
$62M 6.86%
1,258,166
+261,149
+26% +$8.42M
RLAY icon
5
Relay Therapeutics
RLAY
$4.04B
$58.2M 6.44%
6,923,574
+925,000
+15% +$9.95M
RVMD icon
6
Revolution Medicines
RVMD
$38.8B
$50.1M 5.55%
1,810,000
– –
VERV
7
DELISTED
Verve Therapeutics
VERV
$39.2M 4.34%
2,954,710
+594,139
+25% +$9.57M
NTLA icon
8
Intellia Therapeutics
NTLA
$1.5B
$37.3M 4.12%
1,178,075
-96,925
-8% -$3.76M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$29.1B
$35.4M 3.92%
200,000
-80,000
-29% -$15.3M
EXAS
10
DELISTED
Exact Sciences
EXAS
$31.3M 3.47%
459,450
-40,550
-8% -$3.44M
SLGC
11
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$30.1M 3.33%
12,604,275
– –
PLRX icon
12
Pliant Therapeutics
PLRX
$64.4M
$27.3M 3.03%
1,577,108
-122,892
-7% -$2.13M
DNLI icon
13
Denali Therapeutics
DNLI
$3.67B
$26.8M 2.97%
1,300,000
– –
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$21.7M 2.4%
498,427
+474,613
+1,993% +$16.9M
BPMC
15
DELISTED
Blueprint Medicines
BPMC
$18.7M 2.06%
371,378
-248,622
-40% -$13.3M
TNYA icon
16
Tenaya Therapeutics
TNYA
$161M
$16.3M 1.8%
6,381,377
– –
TNGX icon
17
Tango Therapeutics
TNGX
$4.43B
$14.7M 1.63%
1,307,349
+307,349
+31% +$1.87M
BEAM icon
18
Beam Therapeutics
BEAM
$2.66B
$13.7M 1.52%
570,000
– –
FDMT icon
19
4D Molecular Therapeutics
FDMT
$524M
$13.2M 1.46%
1,033,811
-36,189
-3% -$605K
WGS icon
20
GeneDx Holdings
WGS
$1.98B
$11.3M 1.25%
3,095,511
– –
ABCL icon
21
AbCellera Biologics
ABCL
$1.78B
$10.9M 1.2%
2,360,129
-159,871
-6% -$973K
PACB icon
22
Pacific Biosciences
PACB
$444M
$8.65M 0.96%
+1,035,859
New +$11.8M
RNAM
23
DELISTED
Avidity Biosciences
RNAM
$7.97M 0.88%
1,250,000
+400,000
+47% +$3.45M
TSVT
24
DELISTED
2seventy bio
TSVT
$7.93M 0.88%
2,023,913
– –
IPSC icon
25
Century Therapeutics
IPSC
$353M
$6.41M 0.71%
3,206,380
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Casdin Capital held 45 positions worth $904M, down 21% from $1.14B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Casdin Capital withdrew a net $51.9M in Q3 2023, closing 5 positions and reducing 12 holdings. Its most notable exit was CATALENT, INC., an estimated $31.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Casdin Capital opened a new position in Pacific Biosciences worth $8.65M.

  • Casdin Capital's largest Q3 2023 buy was Pacific Biosciences: 1,035,859 shares worth $8.65M.
  • Casdin Capital added most to Mirati Therapeutics, Inc. Common Stock in Q3 2023, an estimated $16.9M increase.
  • Casdin Capital's biggest Q3 2023 reduction was Illumina, cutting an estimated $22M.
  • Casdin Capital fully exited CATALENT, INC. in Q3 2023, selling an estimated $31.2M.
  • Casdin Capital's ten largest holdings make up 70% of its $904M portfolio in Q3 2023.
  • Casdin Capital opened 4 new positions and closed 5 in Q3 2023.
  • Casdin Capital's portfolio value fell 21% quarter-over-quarter to $904M.

Based on Casdin Capital's 13F filing for Q3 2023, filed 14 Nov 2023.